Table 4 List of launched drugs in DrugBank targeting DEGs in the meta-analysis
DEG | Fold change | Drug name | Pharmacological action | Indication |
|---|---|---|---|---|
PSMB8 | 1.890 | Carfilzomib | Inhibitor | Multiple myeloma |
PSMB9 | 2.386 | Carfilzomib | Inhibitor | Multiple myeloma |
PSMB10 | 1.793 | Carfilzomib | Inhibitor | Multiple myeloma |
PSMB2 | 1.590 | Carfilzomib | Inhibitor | Multiple myeloma |
FCGR2A | 1.517 | Intravenous Immunoglobulin | Antagonist | Immunodeficiencies, autoimmune and inflammatory disorders |
FCGR3A | 1.632 | Intravenous Immunoglobulin | Antagonist | Immunodeficiencies, autoimmune and inflammatory disorders |
C5 | 1.981 | Intravenous Immunoglobulin | Binder | Immunodeficiencies, autoimmune and inflammatory disorders |
C5 | 1.981 | Eculizumab | Antibody | Antibody against C5 |
IL1B | 1.629 | Canakinumab | Binder | Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome |
IL1B | 1.629 | Gallium nitrate | Antagonist | Hypercalcemia, non-hodgkin’s lymphoma |
JAK2 | 2.756 | Ruxolitinib | Inhibitor | High-risk myelofibrosis |
JAK2 | 2.756 | Tofacitinib | Antagonist | Rheumatoid arthritis |
TLR7 | 1.899 | Hydroxychloroquine | Antagonist | Malaria |
CD19 | −1.658 | Blinatumomab | Activator | Refractory B-cell precursor acute lymphoblastic leukemia |
CD247 | −1.586 | Muromonab | Binder | Prevention of organ rejection |
CD274 | 1.674 | Atezolizumab | Antibody | Urothelial carcinoma |
IL23A | −1.621 | Ustekinumab | Antibody | Management of moderate to severe plaque psoriasis |
POLB | 1.888 | Cytarabine | Inhibitor | Acute non-lymphocytic leukemia |
S1PR1 | −1.956 | Asfotase Alfa | Agonist | Hypophosphatasia |